These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39116784)

  • 1. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway.
    Mattii L; Moscato S; Ippolito C; Polizzi E; Novo G; Zucchi R; De Caterina R; Ghelardoni S; Madonna R
    Biomed Pharmacother; 2024 Sep; 178():117278. PubMed ID: 39116784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin restores autophagy and attenuates ponatinib-induced cardiomyocyte senescence and death.
    Biondi F; Ghelardoni S; Moscato S; Mattii L; Barachini S; Novo G; Zucchi R; De Caterina R; Madonna R
    Vascul Pharmacol; 2024 Jun; 155():107300. PubMed ID: 38985602
    [No Abstract]   [Full Text] [Related]  

  • 3. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy.
    Madonna R; Barachini S; Moscato S; Ippolito C; Mattii L; Lenzi C; Balistreri CR; Zucchi R; De Caterina R
    Vascul Pharmacol; 2022 Feb; 142():106949. PubMed ID: 34843980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model.
    Madonna R; Moscato S; Polizzi E; Pieragostino D; Cufaro MC; Del Boccio P; Bianchi F; De Caterina R; Mattii L
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation.
    Luo Y; Ye T; Tian H; Song H; Kan C; Han F; Hou N; Sun X; Zhang J
    Lipids Health Dis; 2024 Sep; 23(1):308. PubMed ID: 39334359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.
    Shi Y; Zhao L; Wang J; Liu X; Bai Y; Cong H; Li X
    Cardiovasc Diabetol; 2024 Jul; 23(1):269. PubMed ID: 39044275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
    Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
    Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
    Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy.
    Ren C; Sun K; Zhang Y; Hu Y; Hu B; Zhao J; He Z; Ding R; Wang W; Liang C
    Front Pharmacol; 2021; 12():664181. PubMed ID: 33995090
    [No Abstract]   [Full Text] [Related]  

  • 13. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
    Barış VÖ; Dinçsoy AB; Gedikli E; Zırh S; Müftüoğlu S; Erdem A
    Cardiovasc Toxicol; 2021 Sep; 21(9):747-758. PubMed ID: 34089496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
    Jhuo SJ; Liu IH; Tasi WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34198942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway.
    Chang HY; Hsu HC; Fang YH; Liu PY; Liu YW
    Biomed Pharmacother; 2024 Jul; 176():116759. PubMed ID: 38788603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor.
    Jhuo SJ; Liu IH; Tsai WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32784369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin ameliorates ventricular arrhythmias by inhibiting sympathetic remodeling via nerve growth factor/tyrosine kinase receptor A pathway inhibition.
    Jing Y; Ding Y; Fu H; Li T; Long T; Ye Q
    J Cardiovasc Med (Hagerstown); 2024 Sep; 25(9):664-673. PubMed ID: 38949125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.